"More home monitoring" to counter white-coat syndrome
This article was originally published in Clinica
Executive Summary
It is time to stop using high blood pressure readings documented by general practitioners to make treatment decisions." This is the conclusion of UK research into alternative ways of monitoring blood pressure, which finds that measurements by doctors are likely to be significantly higher than those made in a home or ambulatory setting - thereby providing an inaccurate diagnosis and a worse prediction of response to treatment and adverse outcomes.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.